Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis

被引:84
作者
Achilli, Chiara [1 ]
Pundir, Jyotsna [1 ]
Ramanathan, Parimalam [1 ]
Sabatini, Luca [1 ]
Hamoda, Haitham [2 ]
Panay, Nick [3 ]
机构
[1] St Bartholomews Hosp, Ctr Reprod Med, London EC1A 7BE, England
[2] Kings Coll Hosp London, London, England
[3] Queen Charlottes & Chelsea Hosp, London, England
关键词
Transdermal testosterone; postmenopausal; HSDD; hypoactive sexual desire disorder; SURGICALLY MENOPAUSAL WOMEN; QUALITY-OF-LIFE; REPLACEMENT THERAPY; CONTROLLED-TRIAL; ESTROGEN; PATCH; PREMENOPAUSAL; ANDROGEN; BENEFITS; LIBIDO;
D O I
10.1016/j.fertnstert.2016.10.028
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To systematically review and summarize the existing evidence related to the efficacy and safety of transdermal T in postmenopausal women for the treatment of hypoactive sexual desire disorder (HSDD). Design: Systematic reviews and meta-analysis. Setting: Not applicable. Patient(s): Seven randomized controlled trials enrolled 3,035 participants; 1,350 women were randomized to treatment with T patch, and 1,379 women were randomized to placebo. Intervention(s): None. Main Outcome Measure(s): Primary outcome: satisfying sexual episodes. Secondary outcomes: sexual activity, orgasm, Profile of Female Sexual Function domains (desire), personal distress score, adverse events, acne, increased hair growth, facial hair, alopecia, voice deepening, urinary symptoms, breast pain, headache, site reaction, total adverse events, serious adverse events, withdrawal from study, and follow-up rate. Result(s): The T group had significantly more satisfying sexual episodes, sexual activity, orgasms, desire, significant change in Personal Distress Scale score, androgenic adverse events, acne, and hair growth compared with the placebo group. There was no significant difference between the two groups in increase in facial hair, alopecia, voice deepening, urinary symptoms, breast pain, headache, site reaction to the patch, total adverse events, serious adverse events, reasons for withdrawal from the study, and the number of women who completed the study. Conclusion(s): The short-term efficacy in terms of improvement of sexual function and safety of transdermal T in naturally and surgically menopausal women affected by HSDD either on or not on estrogen progestin hormone therapy is evident from this systematic review. The use of transdermal T is associated with increase in androgenic adverse events such as acne but is not associated with any serious adverse events. (C) 2016 by American Society for Reproductive Medicine.
引用
收藏
页码:475 / +
页数:23
相关论文
共 50 条
  • [1] The 2012 Hormone Therapy Position Statement of The North American Menopause Society
    不详
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2012, 19 (03): : 257 - 271
  • [2] [Anonymous], TESTOSTERONE PERI PO
  • [3] [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
  • [4] Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3
    Barton, Debra L.
    Wender, Donald B.
    Sloan, Jeff A.
    Dalton, Robert J.
    Balcueva, Ernie P.
    Atherton, Pamela J.
    Bernath, Albert M., Jr.
    DeKrey, Wanda L.
    Larson, Tim
    Bearden, James D., III
    Carpenter, Paul C.
    Loprinzi, Charles L.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (09) : 672 - 679
  • [5] Effect of methyl testosterone administration on plasma viscosity in postmenopausal women
    Basaria, S
    Nguyen, T
    Rosenson, RS
    Dobs, AS
    [J]. CLINICAL ENDOCRINOLOGY, 2002, 57 (02) : 209 - 214
  • [6] Hypoactive Sexual Desire Disorder in Postmenopausal Women: Quality of Life and Health Burden
    Biddle, Andrea K.
    West, Suzanne L.
    D'Aloisio, Aimee A.
    Wheeler, Stephanie B.
    Borisov, Natalie N.
    Thorp, John
    [J]. VALUE IN HEALTH, 2009, 12 (05) : 763 - 772
  • [7] Response of the DSM-V Sexual Dysfunctions Subworkgroup to Commentaries Published in JS']JSM
    Binik, Yitzchak M.
    Brotto, Lori A.
    Graham, Cynthia A.
    Segraves, R. Taylor
    [J]. JOURNAL OF SEXUAL MEDICINE, 2010, 7 (07) : 2382 - 2387
  • [8] Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction
    Bluemel, J. E.
    Del Pino, M.
    Aprikian, D.
    Vallejo, S.
    Sarra, S.
    Castelo-Branco, C.
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2008, 24 (12) : 691 - 695
  • [9] Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women - A randomized, placebo-controlled trial
    Braunstein, GD
    Sundwall, DA
    Katz, M
    Shifren, JL
    Buster, JE
    Simon, JA
    Bachman, G
    Aguirre, OA
    Lucas, JD
    Rodenberg, C
    Buch, A
    Watts, NB
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (14) : 1582 - 1589
  • [10] EFFECT OF COMBINED IMPLANTS OF ESTRADIOL AND TESTOSTERONE ON LIBIDO IN POSTMENOPAUSAL WOMEN
    BURGER, H
    HAILES, J
    NELSON, J
    MENELAUS, M
    [J]. BRITISH MEDICAL JOURNAL, 1987, 294 (6577) : 936 - 937